Interesting facts
Interesting Facts about 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid
This compound is a fascinating example of the intricate relationship between structure and biological activity within medicinal chemistry. Here are several noteworthy points that highlight its significance:
- Biological Relevance: 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid is often studied for its potential medicinal properties, particularly in the realm of cancer treatment and other therapeutic applications.
- Structural Complexity: The compound incorporates a pteridine moiety, which is known for its role in various biological processes, including nucleic acid metabolism and as a cofactor in enzymatic reactions.
- Drug Design: Its design reflects principles of structure-activity relationships (SAR) in drug discovery, where slight modifications of the molecular structure can lead to significant changes in biological activity—illustrating the power of molecular engineering.
- Interesting Functional Groups: The presence of both amine and carboxylic acid functionalities allows for diverse interactions in biological systems, enhancing its bioavailability and target affinity.
- Research Implications: Ongoing studies explore the compound's synergistic effects when combined with other treatments, showcasing the importance of multi-target approaches in modern pharmacotherapy.
In summary, 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid exemplifies the rich tapestry of synthetic chemistry as it intersects with biological applications, making it a compound of considerable interest for researchers and students alike. Its complex design not only showcases chemical ingenuity but also stands as a testament to the evolving landscape of drug development.
Synonyms
Amethopterin
60388-53-6
DL-Amethopterin
(+/-)Amethopterin
DL-Methotrexate
(+)-Amethopterin
METHOTREXATE(+/-)
TCMDC-123832
Amethopterin (R,S)
2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid
Methotrexate, (+/-)-
CHEMBL426
Methotrexate;DL-Amethopterin
MLS002701970
99ITO15X8S
2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
NSC-117356
NSC-757113
( inverted exclamation markA)-Methotrexate
DL-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-
L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-
TCMDC-125488
6-Mtx (DL)
2-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid
Methotrexate (hydrate)
(+-)-Methotrexate
D-(-)-Amethopterin hydrate
SR-05000001673
EINECS 262-213-7
L(+)-Amethopterin hydrate
NSC117356
GLUTAMIC ACID, N-(4-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-
Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-
L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]glutamic Acid; (+/-)-Methotrexate; DL-Amethopterin; DL-Methotrexate; NSC 117356;
Prestwick_753
Folex (Salt/Mix)
DL-MTX
Prestwick0_000373
Prestwick1_000373
Prestwick2_000373
Prestwick3_000135
Prestwick3_000373
N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-DL-glutamic acid
N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-DL-glutamic acid
SCHEMBL3712
Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, DL-
UNII-99ITO15X8S
BSPBio_000210
BSPBio_000525
BSPBio_001993
Amethopterin; DL-Amethopterin
ChEMBL_59579
(+/-)-METHOTREXATE
SPECTRUM1500398
SPBio_002446
Amethopterin (hydrate); CL14377 (hydrate); WR19039 (hydrate)
BPBio1_000232
BPBio1_000579
Methotrexate pound>>Amethopterin
SCHEMBL11986730
SCHEMBL20369096
CHEBI:93775
DTXSID40859034
Glutamic acid, N-[p-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, L-(+)-
HMS1569K07
HMS1920L21
HMS2091D16
HMS2096K07
HMS3267F07
HMS3371G08
HMS3403O03
HMS3654M22
HMS3713K07
HMS3869E13
Pharmakon1600-01500398
BCA86579
BCP02078
BCP29918
BDBM50004545
BDBM50600679
NSC757113
AKOS000281496
AKOS024282621
4-Amino-N10-methylpteroylglutamic acid
AB02593
CCG-212689
NCGC00015079-03
NCGC00015079-04
NCGC00015079-07
NCGC00095284-01
NCGC00095284-02
AC-11680
NCI60_041622
SMR001565548
SBI-0053664.P003
HY-121151
Kyselina 4-amino-N10-methylpteroylglutamova
CS-0079546
M1664
NS00001328
EN300-296152
SR-05000001673-1
SR-05000001673-2
BRD-A55424491-001-07-4
BRD-A55424491-001-08-2
BRD-A55424491-001-19-9
Q27165469
L-Glutamic acid, N-4-(2,4-diamino-6-pteridinyl)methylmethylaminobenzoyl-
(MTX)2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid
2-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioicacid
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(MTX)
N-(4-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)GLUTAMIC ACID
N-(4-[[(2,4-Diamino-6-pteridinyl)methyl](methyl)amino]benzoyl)glutamic acid, (L)-
N-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)glutamic acid
N-(p-((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid, (L)-
(methotrexate)2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid
(Methotrexate, MTX)2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid
2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid (Methotrexate)
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid (MTX)
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid bis-adamantan-1-ylamide
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(Amethopterin)
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(Methotrexate (MTX))
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(Methotrexate )
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(methotrexate(MTX))
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(Methotrexate)
2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid(Methotrexate, MXT)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(methotrexate, MTX)
Methotrexate2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid
Solubility of 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid
The solubility of the compound 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid (C19H19N7O6) can be quite complex due to its specific molecular structure, which contains various functional groups influencing its behavior when introduced to solvents. Here are some key considerations:
In summary, while the compound exhibits characteristics that suggest it should have a decent solubility in polar solvents, it is essential to conduct experimental assessments to determine the exact solubility conditions and behaviors.